Multi-Vaccine Platform
Briefly, the project is based on the University of Virginia’s iGem project on bacterial minicells used as a
drug delivery system. We will use their system of making high levels of mini cells, but we’ll use it as a
vaccine platform system. We will also be using the Gibson Assembly method of making large DNA
constructs and the Wolbachia surface protein as our immunogenic factor as well as our epitope
presenting protein. We plan to make a vaccine that can carry more than 5 different antigenic factors,
which means one shot will have more than five types of flu virus or one shot can have antigens against
HIV, HBV, HPV, Tuberculosis, Malaria or any other. This project has a high likelihood of success, since we
are reusing an already established Biobrick and the Wolbachia surface protein is very immunogenic. We
hope that this process will create strong responses for the other antigens.
drug delivery system. We will use their system of making high levels of mini cells, but we’ll use it as a
vaccine platform system. We will also be using the Gibson Assembly method of making large DNA
constructs and the Wolbachia surface protein as our immunogenic factor as well as our epitope
presenting protein. We plan to make a vaccine that can carry more than 5 different antigenic factors,
which means one shot will have more than five types of flu virus or one shot can have antigens against
HIV, HBV, HPV, Tuberculosis, Malaria or any other. This project has a high likelihood of success, since we
are reusing an already established Biobrick and the Wolbachia surface protein is very immunogenic. We
hope that this process will create strong responses for the other antigens.